FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Aubrey de Lavenu Harold Andre		 2. Date of Event Requiring Statement (MM/DD/YYYY)
7/12/2017 

 3. Issuer Name and Ticker or Trading Symbol

CEN BIOTECH INC [CENBF]
(Last)        (First)        (Middle)

300-3295 QUALITY WAY		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

WINDSOR, ONTARIO, CANADA, A6 N8T 3R9      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
4/22/2021 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 13321 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Convertible Note 5/24/2016  (3)Common Stock 62500 (2)$1.6000 D  
Convertible Note 11/25/2016  (3)Common Stock 125000 (2)$1.6000 D  
Convertible Note 12/14/2016  (3)Common Stock 156250 (2)$1.6000 D  
Convertible Note 2/9/2017  (3)Common Stock 312500 (2)$1.6000 D  
Explanation of Responses:
(1) Harold Aubrey de Lavenu (the "Reporting Person") was appointed to his position with CEN Biotech, Inc. (the "Issuer") on July 12, 2017 and owned 13,321 shares of the Issuer's common stock on such date. On April 2, 2021, the Issuer appointed the Reporting Person to serve as a Vice President of the Issuer effective as of April 2, 2021
(2) Additionally the Reporting Person owned convertible notes on July 12, 2017, which the Reporting Person purchased from the Issuer which were at such time and still are convertible into 656,250 shares of the Issuer's common stock.
(3) The convertible notes included in this table matured on May 12, 2018, November 25, 2018, December 14, 2018, and February 19, 2019, respectively, (the "Maturity Dates"), however, the ability to convert the notes into shares did not expire on the Maturity Dates of the notes.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Aubrey de Lavenu Harold Andre
300-3295 QUALITY WAY
WINDSOR, ONTARIO, CANADA, A6 N8T 3R9		X
Signatures
/s/ Harold Aubrey de Lavenu5/28/2021
**Signature of Reporting PersonDate
CEN Biotech (CE) (USOTC:CENBF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos CEN Biotech (CE).
CEN Biotech (CE) (USOTC:CENBF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos CEN Biotech (CE).